Loading organizations...
Trilobio builds an integrated lab automation platform, merging robotics, specialized devices, and proprietary software. It offers biological protocols as code via an app store, streamlining experimental workflows. This solution delivers powerful, accessible automation, aiming to mitigate complexities and high costs associated with biological laboratories.
Co-founded in 2021 by CEO Roya Amini-Naieni and CTO Maximilian Schommer, Trilobio originated from the insight that data quality and reproducibility issues hindered life science research. Amini-Naieni, a Forbes 30 Under 30 honoree, and Schommer combined expertise to address manual lab limits, identifying a crucial need for empowering tools for biologists.
The platform targets biologists and life science researchers seeking enhanced experimental precision and scalable operations. Trilobio's vision centers on democratizing advanced lab robotics, making sophisticated automation widely accessible and user-friendly. The company aims to transform synthetic biology and broader life science, fostering fully automated, highly reproducible scientific discovery.
Trilobio has raised $11.0M across 2 funding rounds.
Trilobio has raised $11.0M in total across 2 funding rounds.
Trilobio has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $8M Seed | Andrew Sather | Neotribe Ventures, Project 11, Argon Ventures, Lowercarbon Capital | Announced |
| Nov 1, 2023 | $3M Seed | — | Climate Capital, Neotribe Ventures, Project 11 | Announced |
Trilobio has raised $11.0M in total across 2 funding rounds.
Trilobio's investors include Andrew Sather, Neotribe Ventures, Project 11, Argon Ventures, Lowercarbon Capital, Climate Capital.
Trilobio is a biotechnology company developing a fully integrated lab automation platform, including the Trilobot robot, hardware tools, and Trilobio OS software, to automate genetic engineering, synthetic biology, molecular biology, microbiology, and biochemistry research.[1][2][3] It serves academic labs, therapeutics companies, and industry researchers by solving reproducibility issues—where 77% of biologists fail to reproduce experiments due to human error—and reducing manual setup, integration, and execution times, enabling walk-away automation and higher throughput at affordable prices.[2][3][4][5] The company has shown strong growth momentum, raising $3 million in pre-seed funding in 2021 and an $8 million seed round recently, launching at SLAS2025 with pilot data demonstrating 25-33% throughput increases and 80 hours of saved training time for customers like Triton Bio and Abalone Bio.[2][3][4]
Trilobio was co-founded in 2021 by Roya Amini-Naieni (CEO) and Maximilian Schommer, both named on Forbes' 30 Under 30 list for Manufacturing & Industry, driven by frustrations with existing lab equipment during their research careers.[2][4] Amini-Naieni quit research after recognizing that current tools hindered creativity and efficiency, inspiring her to build automation "by biologists for biologists" that acts as a superpower for scaling experiments.[4][5] Early traction came from developing the self-calibrating Trilobot and no-code Trilobio OS, securing pre-seed funding from Argon Ventures and Lowercarbon Capital, deploying pilots at leading labs, and debuting the platform at SLAS2025 with customer testimonials on real-world impact.[1][2][3]
Trilobio rides the synthetic biology and lab automation wave, where advances in genetic engineering demand reproducible, high-throughput research to tackle climate, disease, and therapeutics challenges, amplified by AI-driven protocol design.[2][4][5] Timing is ideal post-SLAS2025 launch amid a reproducibility crisis (77% failure rate), with market forces like rising R&D costs and labor shortages favoring affordable, plug-and-play automation over fragmented tools.[1][2][5] It influences the ecosystem by democratizing full-lab automation—previously limited to big pharma—fostering protocol sharing via its app store, accelerating discoveries in biotech, and enabling smaller labs to compete, much like cloud computing transformed software development.[3][4]
Trilobio is poised to deploy its platform industry-wide with $8M seed funding, expanding Trilobot fleets, toolkits, and OS intelligence for multi-lab scalability.[3][4] Trends like AI-biology integration and automated wet labs will propel it, potentially capturing share in a market frustrated by 77% irreproducibility, evolving from startup to standard infrastructure for bio-research.[2][5] As automation becomes table stakes, Trilobio's biologist-first approach could spark an explosion of advances, turning lab inefficiencies into a superpower for global challenges—revolutionizing biology as promised from day one.[4][5]
